Mapping the Invisible Architecture of Disease: Spatial Multi-Omics Technologies, Computational Integration, and the Path Toward Clinical Translation

Tissue is not a bag of cells. It is a coordinated, three-dimensional community whose spatial organization shapes development, homeostasis, and disease, yet this organization is destroyed the moment tissue is dissociated for conventional sequencing. Spatial multi-omics has emerged to close that gap, but the field remains fragmented across technologies, computational strategies, and clinical settings that rarely speak to one another. We conducted a structured narrative synthesis of the spatial multi-omics literature (2016-2026), organized around a five-branch conceptual framework spanning molecular hierarchy, next-generation sequencing- and imaging-based platforms, computational fusion architectures, clinical translation, and deployment barriers. Sources were drawn from peer-reviewed journals indexed in PubMed, Scopus, and Web of Science, supplemented by platform-defining primary reports. Ninety-plus sources converged on several consistent patterns. NGS-based platforms (Visium, Visium HD, Stereo-seq, DBiT-seq) trade spatial precision for unbiased transcriptomic breadth, whereas imaging-based platforms (MERFISH, seqFISH+, Xenium, CosMx) achieve subcellular fidelity at the cost of panel size. Intermediate-fusion architectures, particularly graph-neural-network models such as SpatialGlue, SWITCH, and MultiGATE, now outperform early- and late-fusion approaches for preserving native spatial topology. Clinically, spatially resolved immune-proximity and stromal-exclusion scores outperform bulk immunohistochemistry in predicting immunotherapy response, and multi-omic mapping has nominated actionable targets in oncology, cardiology, and nephrology. Persistent barriers include FFPE incompatibility, terabyte-scale computational burden, algorithmic opacity, and a severe European-ancestry bias that erodes polygenic score accuracy by up to 78% in African-ancestry cohorts. Spatial multi-omics is approaching, but has not yet reached, routine clinical deployment; standardized pre-analytical protocols, interpretable AI, and globally representative biobanking are the rate-limiting steps for translation.